Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is an investigator-initiated, two-year, randomized, controlled, single-center,
open-label, pilot study comparing 3-drug highly active antiretroviral therapy (HAART) to
3-drug HAART plus raltegravir for persons with acute and early HIV-1 infection. The study
will test the hypothesis that use of the integrase inhibitor raltegravir (400 mg BID orally)
to inhibit the integration step of the HIV-1 life cycle in conjunction with HAART in subjects
with recently acquired HIV-1 infection will decrease the number of HIV-1 infected CD4+
T-cells to a greater extent than a 3-drug HAART regimen.